Community-Acquired Pneumonia (CAP) Surveillance

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: August 12, 2011
Last updated: November 4, 2013
Last verified: November 2013

Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.

Condition Intervention
Other: No Drug

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • In vitro Minimal Inhibitory Concentration Detection [ Time Frame: Up to 27 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • In vitro Gene Mutation Detection [ Time Frame: Up to 15 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

whole blood, serum

Enrollment: 560
Study Start Date: September 2010
Study Completion Date: January 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Other: No Drug
It's a surveillance


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Chinese adult (male or female) >/= 18 years old


Inclusion Criteria:

  • Chinese adult (male or female) ≥18 years old
  • Outpatients or inpatients who suffer from CAP

Exclusion Criteria:


  Contacts and Locations
Please refer to this study by its identifier: NCT01416506

Many Locations, China
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer Identifier: NCT01416506     History of Changes
Other Study ID Numbers: 15465, NN1010CN
Study First Received: August 12, 2011
Last Updated: November 4, 2013
Health Authority: China: Ethics committee of the General Hospital of the People's Liberation Army

Keywords provided by Bayer:
Pneumonia, surveillance

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections processed this record on April 21, 2014